Karel Fostier

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells

Gang Chen, Ijeoma Adaku Umelo, Shasha Lv et al. · PLoS ONE · 2013 · 267 citations · Full text

Medicine, Oncology, Pharmacology +17

Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA

Aude Bonehill, Sandra Tuyaerts, An M. T. Van Nuffel et al. · Molecular Therapy · 2008 · 185 citations · Full text

Life Sciences, Immunology, Immunization +16

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

Kim De Veirman, Nathan De Beule, Ken Maes et al. · Cancer Immunology Research · 2017 · 57 citations

Medicine, Immunology, Oncology +17

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway

Kim De Veirman, Eline Menu, Ken Maes et al. · Cancer Letters · 2018 · 55 citations

Medicine, Cancer Biology, Oncology +16